Roche Holding AG (RHHBY)
OTCMKTS
· Delayed Price · Currency is USD
41.79
+0.70 (1.70%)
Jun 12, 2025, 10:02 AM EDT
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
3.84
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
264.29B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Roche Holding AG News
- 1 day ago - Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH) - Benzinga
- 1 day ago - Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems - GlobeNewsWire
- 2 days ago - $101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche. - GlobeNewsWire
- 2 days ago - Green Steel Industry Report 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche. - GlobeNewsWire
- 3 days ago - Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy - Benzinga
- 6 days ago - Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients - Reuters
- 8 days ago - Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - Seeking Alpha
- 8 days ago - Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) - GlobeNewsWire